148 related articles for article (PubMed ID: 36264490)
1. Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.
Novak ER; Deshpande A; Finlay D; Mason JR; Deshpande AJ; Adams PD; Li S
Methods Mol Biol; 2023; 2594():87-95. PubMed ID: 36264490
[TBL] [Abstract][Full Text] [Related]
2. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
3. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
4. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
5. MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53.
Li L; Tan Y; Chen X; Xu Z; Yang S; Ren F; Guo H; Wang X; Chen Y; Li G; Wang H
PLoS One; 2014; 9(11):e113088. PubMed ID: 25405759
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
7.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
8. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiling demonstrates altered characteristics of CD8
Abolhalaj M; Sincic V; Lilljebjörn H; Sandén C; Aab A; Hägerbrand K; Ellmark P; Borrebaeck CAK; Fioretos T; Lundberg K
Cancer Med; 2022 Aug; 11(15):3023-3032. PubMed ID: 35297213
[TBL] [Abstract][Full Text] [Related]
10. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
Yan B; Claxton D; Huang S; Qiu Y
Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
12. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
Zhu G; Cai J; Zhong H
Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
Zeichner SB; Alghamdi S; Elhammady G; Poppiti RJ
Asian Pac J Cancer Prev; 2014; 15(4):1603-9. PubMed ID: 24641375
[TBL] [Abstract][Full Text] [Related]
15. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
Prokocimer M; Molchadsky A; Rotter V
Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
17. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
Rücker FG; Russ AC; Cocciardi S; Kett H; Schlenk RF; Botzenhardt U; Langer C; Krauter J; Fröhling S; Schlegelberger B; Ganser A; Lichter P; Zenz T; Döhner H; Döhner K; Bullinger L
Leukemia; 2013 Feb; 27(2):353-61. PubMed ID: 22810507
[TBL] [Abstract][Full Text] [Related]
18. Association Analyses of
Wen XM; Xu ZJ; Jin Y; Xia PH; Ma JC; Qian W; Lin J; Qian J
Front Immunol; 2021; 12():717527. PubMed ID: 34745095
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations in older adults with acute myeloid leukemia.
Yanada M; Yamamoto Y; Iba S; Okamoto A; Inaguma Y; Tokuda M; Morishima S; Kanie T; Mizuta S; Akatsuka Y; Okamoto M; Emi N
Int J Hematol; 2016 Apr; 103(4):429-35. PubMed ID: 26781615
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Wang Y; Liu Y; Bailey C; Zhang H; He M; Sun D; Zhang P; Parkin B; Baer MR; Zheng P; Malek SN; Liu Y
Oncogene; 2020 Apr; 39(14):3015-3027. PubMed ID: 32060420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]